ImCheck Company
ImCheck Therapeutics is a developing novel therapeutics that target members of the butyrophilin (BTN) super-family of checkpoint molecules.
Technology:
Atrificial Vectors and Immune Cells
Headquarters:
Marseille, Provence-Alpes-Cote d'Azur, France
Founded Date:
2015-01-01
Employees Number:
11-50
Funding Status:
Series C
Investors Number:
18
Total Funding:
172900000
Estimated Revenue:
Less than $1M
Last Funding Date:
2022-07-13
Last Funding Type:
Series C
Register and Claim Ownership